Tumor-related factors are the most important determinants of outcomes in patients with AIDS-related non-Hodgkin lymphoma.
Since the advent of potent combination antiretroviral therapy, the incidence of systemic AIDS-related non-Hodgkin lymphoma (NHL) has decreased, and for those who receive chemotherapy for this condition, survival has improved. To assess the factors associated with complete remission and survival in the era of potent combination antiretroviral therapy, investigators retrospectively evaluated 210 cases of AIDS-related NHL from 15 institutions in Spain. All cases were diagnosed after January 1, 1994, and had received potent combination antiretroviral therapy within 6 months before and/or after NHL diagnosis. Outcomes evaluated in an intent-to-treat analysis included complete remission (lack of evidence of lymphoma lasting for at least 4 weeks),…